RyMed disappointed with verdict in InVision-Plus IV connector patent infringement case

Dec 23 2010

Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed Technologies, Inc., today responded to a mixed verdict in a patent infringement case concerning RyMed's InVision-Plus® with Neutral Advantage™ technology IV connector.

“While we are disappointed in the jury's decision on two of the three patents, the entire matter is not yet resolved”

On December 17, 2010, an eight-person jury in the U.S. District Court of Delaware determined that there was no willful infringement of any patent. Addtionally, the jury found in RyMed's favor on one patent but decided against RyMed on two other patents. All three patents are owned by ICU Medical, Inc., which like RyMed makes IV connectors.

"While we are disappointed in the jury's decision on two of the three patents, the entire matter is not yet resolved," Ryan said. "We believe that RyMed will be vindicated as these proceedings continue to move through the court system. In the meantime, we expect that the availability of our products will not be affected by this verdict."

A poster presentation at the recent 2010 State of the Science Congress on Nursing Research showed that InVision-Plus outperformed six other manufacturers' connectors in suppressing bacteria known to cause catheter-related bloodstream infections (CRBSI). The poster also summarized research showing that In-Vision Plus reduced occlusions 20%-to-84% in clinical settings with cancer patients. Occlusions have been shown by research to lead to CRBSI, the poster noted.